Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women

Journal of Agricultural and Food Chemistry

Volumn 53, Issue 6, 2005, Pages 1938-1944

  Setchell, Kenneth D R ^a,e   Brzezinski, Amnon ^b   Brown, Nadine M ^a   Desai, Pankaj B ^a   Melhem, Murad ^a   Meredith, Trevor ^c   Zimmer Nechimias, Linda ^a   Wolfe, Brian ^a   Cohen, Yoram ^d   Blatt, Yoav ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c Solbar Plant Extracts   (Israel)

^d Biodar Ltd   (Israel)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Genistein; Humans; Isoflavones; Pharmacokinetics; Phytoestrogens; Slow release

Indexed keywords

DAIDZIN; GENISTIN; ISOFLAVONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POSTMENOPAUSE; SLOW RELEASE FORMULATION; SOYBEAN; SUSTAINED RELEASE PREPARATION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; MIDDLE AGED; POSTMENOPAUSE; SOYBEANS;

GLYCINE MAX;

EID: 20144366829     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf0488099     Document Type: Article

References (43)

1. Murphy, P. A. Phytoestrogen content of processed soybean products. Food Technol. 1982, 43, 60-64.
2. Barnes, S.; Kirk, M.; Coward, L. Isoflavones and their conjugates in soy foods: extraction conditions and analysis by HPLC-mass spectrometry. J. Agric. Food Chem. 1994, 42, 2466-2474.
3. Coward, L.; Barnes, N. C.; Setchell, K. D. R.; Barnes, S. Genistein and daidzein, and their γ-glycosides conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J. Agric. Food Chem. 1993, 41, 1961-1967.
4. Franke, A. A.; Custer, L. J.; Cerna, C. M.; Narala, K. K. Quantitation of phytoestrogens in legumes by HPLC. J. Agric. Food Chem. 1994, 42, 1905-1913.
5. Setchell, K. D. R.; Cole, S. J. Variations in isoflavone levels in soy foods and soy protein isolates and issues related to isoflavone databases and food labeling. J. Agric. Food Chem. 2003, 51, 4146-4155.
6. Setchell, K. D. R. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr. 1998, 68, 1333S-1346S.
7. Setchell, K. D. R.; Borriello, S. P.; Hulme, P.; Kirk, D. N.; Axelson, M. Nonsteroidal estrogens of dietary origin: possible roles in hormone- dependent disease. Am. J. Clin. Nutr. 1984, 40, 569-578.
8. Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262, 5592-5595.
9. Adlercreutz, H.; Mousavi, Y.; Clark, J.; Hockerstedt, K.; Hamalainen, E., et al. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem. Mol. Biol. 1992, 41, 331-337.
10. Peterson, G.; Barnes, S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993, 22, 335-345.
11. Barnes, S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr. 1995, 125, 777S-783S.
12. Kim, H.; Peterson, T. G.; Barnes, S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr. 1998, 68, 1418S-1425S.
13. Diel, P.; Schulz, T.; Smolnikar, K.; Strunck, E.; Vollmer, G., et al. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: estrogenicity profiles and uterotropic activity. J. Steroid Biochem. Mol. Biol. 2000, 73, 1-10.
14. Messina, M. J. Legumes and soybeans: overview of their nutritional profiles and health effects. Am. J. Clin. Nutr. 1999, 70, 439S-450S.
15. Geil, P. B.; Anderson, J. W. Nutrition and health implications of dry beans: a review. J. Am. Coll. Nutr. 1994, 13, 549-558.
16. FDA Food Labeling. Health claims, soy protein, and coronary heart disease. Fed. Regist. 1999, 699-733.
17. Axelson, M.; Sjovall, J.; Gustafsson, B. E.; Setchell, K. D. R. Soya - a dietary source of the non-steroidal oestrogen equol in man and animals. J. Endocrinol. 1984, 702, 49-56.
18. Karr, S. C.; Lampe, J. W.; Hutchins, A. M.; Slavin, J. L. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. Am. J. Clin. Nutr. 1997, 66, 46-51.
19. Watanabe, S.; Yamaguchi, M.; Sobue, T.; Takahashi, T.; Miura, T., et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J. Nutr. 1998, 128, 1710-1715.
20. Izumi, T.; Piskula, M. K.; Osawa, S.; Obata, A.; Tobe, K., et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J. Nutr. 2000, 130, 1695-1699.
21. Seow, A.; Shi, C. Y.; Franke, A. A.; Hankin, J. H.; Lee, H. P., et al. Isoflavonoid levels in spot urine are associated with frequency of dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore. Cancer Epidemiol. Biomarkers Prev. 1998, 7, 135-140.
22. Busby, M. G.; Jeffcoat, A. R.; Bloedon, L. T.; Koch, M. A.; Black, T., et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am. J. Clin. Nutr. 2002, 75, 126-136.
23. Shelnutt, S. R.; Cimino, C. O.; Wiggins, P. A.; Badger, T. M. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiol., Biomarkers Prev. 2000, 9, 413-419.
24. Zubik, L.; Meydani, M. Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am. J. Clin. Nutr. 2003, 77, 1459-1465.
25. Setchell, K. D. R.; Brown, N. M.; Desai, P. B.; Zimmer-Nechimias, L.; Wolfe, B., et al. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J. Nutr. 2003, 133, 1027-1035.
26. Setchell, K, D. R.; Brown, N. M.; Desai, P.; Zimmer-Nechemias, L.; Wolfe, B. E., et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 2001, 131, 1362S-1375S.
27. Bloedon, L. T.; Jeffcoat, A. R.; Lopaczynski, W.; Schell, M. J.; Black, T. M., et al. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am. J. Clin. Nutr. 2002, 76, 1126-1137.
28. Erdman, J. W., Jr.; Stillman, R. J.; Boileau, R. A. Provocative relation between soy and bone maintenance. Am. J. Clin. Nutr. 2000, 72, 679-680.
29. Messina, M.; Hughes, C. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J. Med. Food 2003, 6, 1-11.
30. Setchell, K. D. R.; Lydeking-Olsen, E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am. J. Clin. Nutr. 2003, 75, 593S-609S.
31. Setchell, K. D. R.; Brown, N. B.; Lydeking-Olsen, E. The clinical importance of the metabolite equol - A clue to the effectiveness of soy and its isoflavones. J. Nutr. 2002, 132, 3577-3584.
32. King, R. A.; Bursill, D. B. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am. J. Clin. Nutr. 1998, 67, 867-872.
33. Fanti, P.; Sawaya, B. P.; Custer, L. J.; Franke, A. A. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J. Am. Soc. Nephrol. 1999, 10, 864-871.
34. 13C]labeled tracers in premenopausal women. Am. J. Clin. Nutr. 2003, 77, 411-419.
35. Setchell, K. D. R.; Brown, N. M.; Zimmer-Nechemias, L.; Brashear, W. T.; Wolfe, B.; Kirschner, A. S.; Heubi, J. E. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am. J. Clin. Nutr. 2002, 76, 447-453.
36. 13C]daidzein. J. Med. Food 1999, 2, 99-102.
37. Gibaldi, M.; Perrier, D. Pharmacokinetics, 2nd ed., revised and expanded; Dekker. New York, 1982.
38. Gibaldi, M. Biopharmaceutics and Clinical Pharmacokinetics, 4th ed.; Lea and Febiger: Philadelphia, PA, 1991.
39. Jayagopal, V.; Albertazzi, P.; Kilpatrick, E. S.; Howarth, E. M.; Jennings, P. E., et al. beneficial effects of soy phytoestrogen intake in postmenopausal women with Type 2 diabetes. Diabetes Care 2002, 25, 1709-1714.
40. Zhang, Y.; Wang, G. J.; Song, T. T.; Murphy, P. A.; Hendrich, S. Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity. J. Nutr. 1999, 129, 957-962.
41. Setchell, K. D. R.; Welsh, M.; Lim, C. HPLC analysis of phytoestrogens in soy protein preparations with ultraviolet, electrochemical, and thermospray mass spectrometric detection. J. Chromatogr. 1987, 385, 267-274.
42. Xu, X.; Wang, H. J.; Murphy, P. A.; Hendrich, S. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J. Nutr. 2000, 130, 798-801.
43. Day, A. J.; DuPont, M. S.; Ridley, S.; Rhodes, M.; Rhodes, M. J., et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β-glucosidase activity. FEBS Lett. 1998, 436, 71-75.